Brind.

FDA accepted NDA for zilurgisertib in FOP, following collaboration on the PROGRESS study between Mirum Pharmaceuticals and Incyte.

2 reports, 2 independent Updated Sep 1

No new developments lately

Reports: 2
Developments: 1
Repetition: 50%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 2 outlets

FDA accepted NDA for zilurgisertib in FOP, following collaboration on the PROGRESS study between Mirum Pharmaceuticals and Incyte.

Who's involved

What this event is mainly about

FDA Mirum Pharmaceuticals Incyte

Keep exploring

The entities involved

FDA
- Generic medicine services are seeking approval for launch from the FDA.Mon 17:49
- A company is seeking FDA feedback on its NEO212 program, with a meeting scheduled at the FDA's White Oak campus.Mon 14:56
Mirum Pharmaceuticals
biopharmaceutical company
- Trump's pledge to unleash oil and gas benefits stocks, specifically impacting Mirum Pharmaceuticals.Sun 07:23
Incyte
American pharmaceutical company
- Incyte, a biotech company based in Wilmington, outperformed the biotech ETF.Thu 13:11

Related events

Data was presented in Athens supporting a future U.S. NDA submission to the FDA.Sep 4

Coverage

Newest first; wire copies grouped

Sep 1finanznachrichten.de
Jun 14stockhouse.com